The key factors propelling the growth of the rheumatoid arthritis drugs market are the launch of new biosimilars, rising prevalence of arthritis, and an increase in the acceptance of biopharmaceuticals.
The major factors that fuel the growth of the market are the growing burden of rheumatoid arthritis disease with the increasing geriatric population. It usually affects the geriatric population, and the prevalence is seen higher in females as compared to males. Therefore, larger cases of this disease can be found in aged population reaching hospitals.
There are also several therapeutics and medications that have been developed in the recent years, to treat the symptoms of rheumatoid arthritis. Rheumatoid arthritis drugs management is generally associated with a high cost. Most commonly used drugs are disease-modifying anti-rheumatic drugs, non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and biologic drugs. The biologics account for a prominent market share, in terms of revenue, due to the considerably high cost of these medicines. However the costs of rheumatoid arthritis drugs and NSAIDs are less than biologics. Thus, growing availability and awareness of safer drugs are anticipated to increase the global rheumatoid arthritis drugs market.
Key Market Trends
NSAIDs, by Drug Class is Expected to be the Largest Segment Over the Forecast Period
NSAIDs are being widely utilized for the symptomatic treatment of rheumatic disorders. Disease-modifying anti-rheumatic drugs (DMARDs) are also considered as the gold standard for the treatment of moderate to severe rheumatoid arthritis. Unlike conventional DMARDs, the NSAIDs give symptomatic relief, biologic drugs are more efficient in the management of rheumatoid arthritis.
The increasing prevalence of the disease globally is boosting the segment growth. With the growing number of arthritis cases, the use of NSAIDs and their production is expected to observe healthy demand and supply throughout the forecast period. As per a 2017 publication in Morbidity and Mortality Weekly Report, by 2040, an estimated 78 million (26% United States adults aged 18 years or older are projected to have doctor-diagnosed arthritis. This shows a steady growth in arthritic cases, supporting the expected growth of NSAIDs in the market.
Asia-Pacific is Witnessing High Growth and is Expected to Follow the Same Trend Over the Forecast Period
The Asia-Pacific market is projected to witness high growth during the forecast period, due to increasing healthcare expenditure. Moreover, the low cost of manufacturing in China and India has resulted in the rise in the production facilities, attracting pharmaceutical and biotechnological giants to the Asia-Pacific region from across the world.
The increase in the incidence of rheumatoid arthritis disease is also expected to fuel the market in the region during the forecast period. For instance, as per the Institute for Health Metrics and Evaluation, the number of cases of rheumatoid arthritis has increased from 183,272 in 2007 to 263,365 in 2017 only in India. Therefore, analyzing the number of cases in other major countries of the Asia Pacific region, the healthcare activities in relation to the treatment of rheumatoid arthritis would require large and continuous support from everyone.
A majority of rheumatoid arthritis drug products are being manufactured by key players. The market leaders in this industry have established their position in the market, and these manufacturers have a wide product range to offer and have an extensive distribution system across the world. Additionally, the emerging markets in the Asia-Pacific region are witnessing the entry of small players.
Reasons to Purchase this report:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support